Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Evolus, Inc. (NASDAQ:EOLS - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 72,608 shares of the company's stock, valued at approximately $873,000. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.11% of Evolus as of its most recent SEC filing.
A number of other large investors have also added to or reduced their stakes in the company. Vanguard Group Inc. raised its position in Evolus by 2.0% during the first quarter. Vanguard Group Inc. now owns 3,234,068 shares of the company's stock valued at $38,906,000 after purchasing an additional 62,664 shares in the last quarter. XTX Topco Ltd purchased a new stake in Evolus during the first quarter valued at about $742,000. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in Evolus during the first quarter valued at about $151,000. Y Intercept Hong Kong Ltd purchased a new stake in Evolus during the first quarter valued at about $449,000. Finally, IFP Advisors Inc raised its position in Evolus by 99.0% during the first quarter. IFP Advisors Inc now owns 9,427 shares of the company's stock valued at $113,000 after purchasing an additional 4,691 shares in the last quarter. Hedge funds and other institutional investors own 90.69% of the company's stock.
Evolus Trading Up 3.2%
Shares of NASDAQ EOLS traded up $0.2350 during trading hours on Friday, hitting $7.6650. The company's stock had a trading volume of 253,747 shares, compared to its average volume of 1,101,574. The company has a debt-to-equity ratio of 22.00, a quick ratio of 1.86 and a current ratio of 2.27. The stock has a market cap of $495.81 million, a price-to-earnings ratio of -7.83 and a beta of 1.12. Evolus, Inc. has a 12 month low of $5.71 and a 12 month high of $17.82. The business has a 50-day simple moving average of $8.67 and a 200-day simple moving average of $10.68.
Insider Buying and Selling
In other Evolus news, Director Brady Stewart bought 30,000 shares of the business's stock in a transaction that occurred on Friday, August 15th. The shares were bought at an average cost of $6.82 per share, with a total value of $204,600.00. Following the completion of the purchase, the director directly owned 88,629 shares of the company's stock, valued at $604,449.78. This trade represents a 51.17% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider David Moatazedi sold 16,582 shares of the firm's stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $9.89, for a total transaction of $163,995.98. Following the completion of the sale, the insider owned 364,927 shares of the company's stock, valued at $3,609,128.03. This trade represents a 4.35% decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is owned by insiders.
Wall Street Analysts Forecast Growth
A number of research analysts have recently issued reports on the company. BTIG Research reduced their price objective on Evolus from $21.00 to $18.00 and set a "buy" rating on the stock in a research note on Wednesday, August 6th. Wall Street Zen cut Evolus from a "hold" rating to a "sell" rating in a research note on Saturday, August 9th. HC Wainwright reduced their price objective on Evolus from $27.00 to $20.00 and set a "buy" rating on the stock in a research note on Wednesday, August 6th. Finally, Needham & Company LLC reaffirmed a "hold" rating and set a $22.00 price objective on shares of Evolus in a research note on Wednesday, August 6th. Four investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, Evolus presently has a consensus rating of "Moderate Buy" and an average price target of $21.25.
Read Our Latest Analysis on EOLS
About Evolus
(
Free Report)
Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.
Further Reading
Before you consider Evolus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evolus wasn't on the list.
While Evolus currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access